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TISSUEGENE-C (TG-C) IMPROVED CLINICAL SCORES IN PATIENTS
WITH OSTEOARTHRITIS: A PHASE 2B STUDY
B. Lee, J. Cho, T. Kim, Y. Park, E. Jeong, K.-H. Lee. Kolon Life Sci., Inc.,
Gwacheon-si, Republic of Korea
Purpose: TG-C is a cell mediated gene therapy that contains non-
transduced (hChonJ) and transduced (hChonJb#7) human allogeneic
chondrocytes. The hChonJb#7 cells were transduced with TGF-b1 gene
by using retroviral vector and irradiated with gamma-ray. TG-C has
been proved its efﬁcacy and safety in preclinical studies in vitro and in
vivo. TG-C has been tested in Phase I and Phase IIa clinical studies in
osteoarthritis (OA) patients and has proved its safety and efﬁcacy in the
patients.
Methods: The current placebo controlled phase IIb study was con-
ducted to determine both safety and efﬁcacy of TG-C in patients with OA
of the knee. Participants (n¼ 54) with a conﬁrmed diagnosis of knee OA
by X-ray and MRI were randomized into the treatment group (TG-C, 1.8
 107 cells/knee, n ¼ 27) and the placebo group (saline, n ¼ 27). The
primary evaluation parameter was International Knee Documentation
Committee (IKDC) which measures pain, sports activities, and daily
function. The secondary evaluation parameters were Western-Ontario
and MacMaster University (WOMAC) score, Knee Injury and Osteo-
arthritis Outcome Score (KOOS), and 100 mm Visual Analogue Scale
(VAS). These parameters were assessed at 12 and 24 weeks post
treatment. For TG-C treatment group, we also evaluated the all evalu-
ation parameters at 48 weeks post treatment. Additionally, changes in
biomarkers were assessed in serum and urine samples. Safety meas-
ures, including physical exams, complete blood count, and serum
chemistry were included up to 6 months post treatment. Blood samples
were screened to detect the replication competent retrovirus (RCR),
retrovirally transduced cells, and TGF-b1 DNA and protein starting from
2 weeks up to 6 months post treatment.
Results: TG-C treatmentgroup showed improvement in IKDC, WOMAC,
KOOS and 100 mm VAS scores compared toplacebo group as shown in
Table 1.Table 1
Changes in Scores of the Primary and the Secondary Evaluation Parameters at 24
weeks or 48 weeks post treatment, ITT set
TG-C(N ¼ 27) Placebo(N ¼ 27) P values
Primary
endpoint
IKDC, 24W 16.39  15.63 8.05  11.18 P ¼ 0.0304
IKDC, 48W 16.96  16.30 – P ¼ 0.00017
Secondary
endpoint
WOMAC, 24W 13.81  19.23 7.50  13.02 P ¼ 0.1692
WOMAC, 48 W 19.35  19.86 – P ¼ 0.00034
KOOS, 24W 22.96  27.15 13.92  16.85 P ¼ 0.1508
KOOS, 48W 29.15  29.31 – P ¼ 0.00028
VAS, 24W 24.83  27.29 10.79  18.22 P ¼ 0.0321
VAS, 48 W 33.35  29.10 – P ¼ 0.000021) Data for 48 weeks were TG-C treatment group.
2) The p value of 48 weeks were calculated with a comparison between
baseline to 48 weeks.
Conclusions: In summary, this Phase IIb study indicated that TG-C
treatment improved pain, sports activities, and quality of daily life in
patients with knee OA when compared to the placebo control.
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RANDOMIZED, SINGLE CENTER, OBSERVER-BLIND, PARALLEL-
GROUP TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF
HYADD4-G A VISCOELASTIC HYDROGEL, FOR THE TREATMENT OF
MENISCUS TEAR
C. Zorzi y, S. Rigotti y, N. Giordan z, V. Madonna y, V. Condello y,
F. Cortese y, V. Iacono y. yOrthopaedic and Traumatology Dept.,
Sacrocuore Negrar Hosp., Negrar (VR), Italy; z Fidia Farmaceutici S.p.A,
Abano Terme (PD), Italy
Purpose: Injury to themeniscus may play a key role in the development
of knee osteoarthritis (OA) and prior studies demonstrated that tear of
the meniscus are more common in patients with knee OA. Tears present
as severe pain, swelling and possible catching, difﬁculty on deep knee
bending and locking of the knee in partial ﬂexion. Basically, signs and
symptoms of meniscal tears are those of any OA disease where the
reduction of rheological properties of synovial ﬂuid of the affected jointincreases the susceptibility of the articular cartilage to damage. Clinical
trials have demonstrated the efﬁcacy of viscosupplementation in
patients undergoing arthroscopic partial meniscectomy with results on
pain reduction, better joint mobility and reduction of NSAIDs intake. On
this basis we aim to investigate whether intra-articular injections of
HYADD4-G (Hymovis) in patients with meniscal tears could improve
symptoms and knee functionality so to avoid arthroscopy surgery to the
patient.
Methods: This is a single site, randomised, parallel groups, observer-
blind, investigator initiated study. Upon signature of the informed
consent and satisfaction of all inclusion and exclusion criteria, each
patient was randomly assigned to control group, receiving only con-
servative treatment or to HYADD4-G group. Conservative treatment
consisted in use of an immobilizer brace, a combination of rest and ice,
knee off-loading and acetaminophen as per patient’s need. Patients
allocated to HYADD4-G group in addition to the conservative treat-
ment underwent to 2 injections of HYADD4-G two weeks apart: at
visit V1 (day 0) and at visit V2 (day 14). Pain was investigated through a
Visual Analogue Scale (VAS), knee pain stiffness and functionality
through the WOMAC questionnaire. Secondary objectives are the
evaluation of Quality of life by the SF-36 questionnaire, patient’s and
investigator’s global assessment of the disease (PTGA/COGA), intake of
analgesics and HYADD4-G safety. Meniscus tears were evaluated at
baseline and at the following visits by magnetic resonance imaging
scans. The study analyzed the relationship between the symptoms and
the presence of a meniscus tears.
Results: Fifty patients (25 in each of the two treatment groups) were
enrolled in the study. All patients receiving HYADD4-G in addition to
the conservative treatment completed the study, while only 17 out of
the 25 patients in the control group attended the visit 4 (day 60).
Reasons for discontinuing the study were lost to follow-up (4 patients),
surgery before visit 3 (3 patients) and treatment failure (1 patient). Pain
mean values decreases from 82.0 mm at baseline to 12.0 mm at V4 (day
60) in patients receiving HYADD4-G injection while in the control
group VAS pain decreases from 83.6 mm to 57.9 at V4 (day 60). Among
patients who completed the study a statistically signiﬁcant difference
was found between the groups at day 30 up to the end of the study at
day 60 (P < 0.001). Results obtained on pain were conﬁrmed by
WOMAC assessment. WOMAC pain sub-score, stiffness and function
showed the same trend. In particular considering WOMAC pain a stat-
istical signiﬁcant difference between two groups was found at day 30
and this difference persisted to day 60 (P < 0.001). No local or systemic
serious adverse events were observed during the study. Five patients
complained of local pain after injection. Four patients (3 included in
control group and 1 in HYADD4-G group) reported a worsening of the
baseline conditions; these events resulted in withdrawals from the
study.
Conclusion: Although it should be noted that the gold standard for the
evaluation of meniscus injuries is arthroscopic surgery, this study
demonstrates that patients who have been administered HYADD4-G
can improve their symptoms relief since 14 days after the ﬁrst treat-
ment and this decrease was maintained up to 60 days. Symptoms relief
together with MRI data are favourable to HYADD4-G study group,
suggesting a relationship of meniscus injury pain reduction and phys-
ical improvement in knee. In conclusion based on this study HYADD4-
G seems to be indicated for the treatment of pain in patients affected by
meniscal tear or degenerative signal but further investigations need to
be conducted on other symptoms related to this condition to conﬁrm
these promising data.
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TIBIAL SLOPE AND PATELLAR HEIGHT CHANGES FOLLOWING HIGH
TIBIAL OSTEOTOMY
W.S. Osman, M.G. Yousef, M.A. El Gebeily, R.G. Metwaly. Ain Shams
Univ., Cairo, Egypt
Objective: Improving the accuracy of high tibial osteotomy not only in
the coronal plane but with considering it as a three dimension proce-
dure can give better long term results in cases of medial compartment
osteoarthritis associated with varus deformity and minimize the
obstacles faced in future total knee replacement (TKR).
Design: Two different techniques of high tibial osteotomy: the opening
wedge (OWO) and the hemicallotasis osteotomy (HCO) were compared
clinically in a prospective randomized clinical trial that was held in Ain
Shams University hospitals in the period between December 2010 to
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S195April 2013 on thirty knees of twenty-four patients suffering from
medial compartment osteoarthritis associated with varus deformity.
The patients were allocated randomly (single-blinded) in two groups;
where ﬁfteen knees of group (I) underwent high tibial osteotomy using
the OWO technique, while those of group (II) underwent the procedure
using the HCO technique.
Two important parameters were compared; the posterior tibial slope in
lateral radiographs using the anatomical proximal tibial axis and the
patellar height using the Blackburne-Peel method; to assess the accu-
racy of the procedure in the sagittal plane.
Results: OWO had proven lower accuracy than HCO as regard the
change in tibial slope (P ¼ 0.001 and 0.3 respectively), while both
techniques preserved patellar height almost unchanged with optimiz-
ing the procedures’ techniques (P ¼ 0.4 and 0.6 respectively).
Conclusion: HCO technique for osteoarthritic knees associated with
varus deformity can give more accurate results for the sagittal limb
alignment and this may improve the long term results of the procedure
and facilitate future TKR.
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CLINICAL EFFICACY OF PLASMA RICH IN GROWTH FACTORS INTRA-
ARTICULAR INFILTRATIONS IN THE TREATMENT OF KNEE
OSTEOARTHRITIS: A SYSTEMATIC REVIEW
S. Padilla, J. Aguirre, R. Prado, G. Orive, E. Anitua. BTI IMASD, Vitoria,
Spain
Purpose: Osteoarthritis (OA) is a multifactorial polygenic degenerative
disease, mechanically induced, and whose progression might be
attributable to pro-inﬂammatory signaling molecules (cytokines)
overall leading to the synovial joint failure as organ, and where pain
represents the clinical hallmark of disease. This study reviews the
efﬁcacy of the autologous biological therapy, Plasma rich in growth
factor (PRGF) to regenerate tissue and reduce pain in patients with knee
OA.
\Methods: Using the interchangeable terms PRGF, or Plasma rich in
growth factors, or autologous growth factors, or platelet rich plasma,
and knee osteoarthritis, a comprehensive literature search was
conducted using OVID, EMBASE, PASCAL, PubMed/MEDLINE elec-
tronic databases and the Cochrane Central Register of Controlled
Trials on October 31, 2013. Studies were considered suitable if the
participants were over 18 years and had been clinically diagnosed
with OA of the knee according to the American College of Rheu-
matology. The studies had to include a PRGF group and a control
group (Hyaluronic acid, placebo, or another PRP), and the design had
to be a comparative retrospective study or randomized controlled
trial (RCT). Pre- and post-treatment measures of joint pain, reduced
function and stiffness were evaluated using WOMAC, KOOS, IKCD,
LEQUESNE, or OMERAT OARSI responders, with a follow-up of at
least 4 weeks. Studies conducted using methods other than PRGF
(such us double centrifugation, presence of leukocytes, platelet
activation by bovine thrombin) to elaborate the product treatment
group, were excluded. Outcomes were categorized by types and by
pre- and post-treatment numbers, and median, or mean values (SD)
were extracted. Dichotomic variables were expressed by determi-
nation of absolute and relative frequencies and the measure of effect
was calculated by ascertaining the relative risk or odds ratio with
their respective 95% conﬁdence intervals. Quantitative variables were
summarized by using the mean and standard deviation with inter-
vals conﬁdence at 95%. The quality assesment encompassed study
methods, participants, experimental intervention, and control treat-
ment. Overall, the risk of bias was categorized as low, unclear, or
high risk based on random sequence generation, allocation con-
cealment, blinding, incomplete outcome data, and selective
reporting.
Results: The literature research yielded 91 citations, but only pub-
lications using eligible PRGF met the inclusion criteria, consisting of 3
RCTs, 1 prospective and 1 retrospective analysis (n ¼ 5). Two studies
were rated as having a low risk of bias, and the remaining three studies
as having high risk of bias. In two randomized clinical trials, it was
observed that after six months of treatment the number of patients
with a pain reduction of more than 50% was signiﬁcantly higher in the
group treated with PRGF than in the control group (HA). In two other
studies (one retrospective and one prospective) the patients treated
with PRGF showed a signiﬁcant pain reduction compared with the
patients treated with HA (WOMAC and VAS scale respectively). Theremaining variables (WOMAC scale for pain, function, and stiffness,
LEQUESNE, KOOS, scale and OMERAT OARSI responders) showed a
statistically signiﬁcant superiority of the group treated with PRGF in
two RCT (Vaquerizo et al 2013, and Say et al 2013).
Conclusions: The current clinical evidence suggests that pain reduction
of PRGF intra-articular inﬁltrations in patients with knee OA is sig-
niﬁcantly higher compared with HA, and lasting for a longer period of
time (24 weeks after the last inﬁltration). Despite the high risk of bias of
the other three studies, their results are consistent with those coming
from the two RCT. There exist three key limitations in this review: the
heterogeneity of the studies that met the inclusion criteria, the small
number of publications included in the study, and the absence of a
placebo in the control group.
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LOW COST MINIMALIST SHOE AS A MECHANICAL TREATMENT FOR
ALGO-FUNCTIONAL ASPECTS AND ANALGESIC MEDICINE INTAKE IN
ELDERLY WOMEN WITH KNEE OSTEOARTHRITIS
F. Trombini-Souza, A. Matias, M. Yokota, C. Schainberg, R. Fuller,
I.C. Sacco. Univ. of Sao Paulo, Sao Paulo, Brazil
Purpose: To evaluate the therapeutic effect of a low cost, ﬂexible non-
heeled shoe on the WOMAC domains and paracetamol intake of elderly
women with knee OA.
Methods: A randomized, parallel and controlled clinical trial, with blind
assessor was carried out. Fifty-six elderly women with knee OA graded
2 or 3 (Kellgren and Lawrence), assessed at baseline (T0), after three
(T3) and after six months (T6), were randomly allocated into the
intervention group (IG, n ¼ 28) or the control group (CG, n ¼ 28). We
adopted theWOMAC pain as a primary outcome, and stiffness, function,
and total WOMAC score, and paracetamol intake as the secondary
outcomes. As intervention, the patients wore a minimalist, ﬂexible and
low-cost shoe (Moleca shoe; Calçados Beira Rio S.A., Novo Hamburgo,
RS, Brazil) for average daily usage time of 7 h 40 min. This intervention
shoe is a women’s double canvas ﬂexible ﬂat walking footwear without
heels, and with a 5-mm anti-slip rubber sole. Paracetamol (500 milli-
grams), as a rescuemedication, was allowed for both groups only in case
of pain. The time effects (baseline, 3 and 6months) of group (IG and CG)
and interaction (time and group) were tested by two-way casewise
ANOVA.
Results: The IG showed an improvement in pain (effect size
between-group of 1.41), function (effect size of 1.22), and stiffness
(effect size of 0.76) in WOMAC. The within-group results show that
the IG improved the WOMAC pain by 51% (p ¼ 0.001) at T3 and 66%
(p ¼ 0.001) at T6. The CG improved the WOMAC pain by 34% (p ¼
0.001) at T3 and 28% (p ¼ 0.001) at T6. The IG improved the
WOMAC stiffness by 55% (p ¼ 0.001) versus the CG that worsened
22% (p ¼ 0.001) at T3; at T6, the IG presented a reduction of 62% (p
¼ 0.001) for WOMAC stiffness while, in the CG, the reduction was
only by 15% (p ¼ 0.001). The IG increased the WOMAC function by
52% (p ¼ 0.001) at T3 and 62% (p ¼ 0.001) at T6. In the CG, this
variable was improved by 29% (p ¼ 0.001) at T3 and 19% (p ¼ 0.001)
at T6. In the IG, WOMAC total score was improved by 53% (p ¼
0.001) at T3 and 62.4% (p ¼ 0.019) at T6. In CG the improvement
was of 26% (p ¼ 0.001) at T3 and 19% (p ¼ 0.001) at T6. The CG
increased signiﬁcantly the intake of rescue medication throughout
the study, which possibly inﬂuenced their pain reduction and
function improvement. The IG showed a slight increase in the par-
acetamol intake at the end of the 1st, 2nd and 3rd month; never-
theless, in the 4th, 5th and 6th month, the paracetamol intake was
again similar to the initial assessment. From the 2nd to 6th month
paracetamol intake was signiﬁcantly higher in CG compared to IG.
Conclusion: We can recommend the use of this low cost minimalist
shoe as another conservative mechanical treatment that aims to mini-
mize pain, improve functional aspects, and reduce the rescue medi-
cation intake.
338
BMI, OBESITY AND EDUCATION
N.L. Brito, M.U. Rezende, M.I. Hissadomi, A.F. Pailo, T. Pasqualin,
G.C. Campos, R. Frucchi. Faculdade Med. USP, Sao Paulo, Brazil
Purpose: To evaluate the effects of an educational program of patients
with knee osteoarthritis (KOA) by means of BMI change.
